Cytokinetics aims to become the Vertex of cardiovascular disease

Cytokinetics is not letting the small matter of losing a big biotech partner get it down. Amgen walked away from the heart failure project omecamtiv mecarbil in 2020, but the smaller group believes it has found a niche it can pursue alone, at least in the US – and it has even grander long-term plans.